Why titration exists

The dose-limiting effects of GLP-1 agonists — nausea, vomiting, constipation, early satiety — are largely a function of the rate of change rather than the absolute dose. Tolerance to the gastrointestinal effects develops over weeks at a given dose, which is why the labelled schedules hold each step for a fixed period before increasing.

Escalating faster than the label is the most common self-directed modification, and it is also the most common reason people abandon treatment entirely. The schedule is not conservative padding; it is the reason the trials achieved the adherence they did.

How the timeline works

Each product has its own step sequence — a starting dose, a series of increases at fixed intervals, and a maintenance dose that continues open-ended. The chart renders these as a step function, so a dose change appears as a vertical jump rather than a slope, which is what actually happens.

Entering a start date shows your current position on the schedule and the week your maintenance dose is reached. Where a step is open-ended, the timeline extends it to the end of the displayed window.

Oral GLP-1s titrate differently

Orforglipron (Foundayo), approved 1 April 2026, is the first oral GLP-1 for weight management without food or water restrictions — a practical difference from oral semaglutide, which must be taken fasted with a small sip of water and a 30-minute wait.

Its ladder runs 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg, with each step held for at least 30 days. That is a longer hold than the four-week steps used by the weekly injectables, and the full titration to maximum dose therefore takes around five months.

Because the label specifies days rather than weeks, the timeline here renders each step as four weeks — very slightly shorter than 30 days. The chart therefore runs marginally ahead of the label rather than behind it.

When the schedule should slow down

Labelled schedules are a default, not a mandate. If side effects at a given step have not settled by the time the next increase is due, holding at the current dose for an additional interval is a recognised and common clinical adjustment. Some people never reach the top maintenance dose and do perfectly well below it.

Dose escalation decisions belong with whoever prescribes. This tool shows what the labelled schedule says; it does not know your tolerability or your indication.

Frequently asked questions

What is the orforglipron (Foundayo) titration schedule?

Orforglipron steps 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg, holding each dose for at least 30 days before increasing. Full titration to the 17.2 mg maximum therefore takes roughly five months. It is a once-daily oral tablet and, unlike oral semaglutide, carries no food or water restrictions.

Why do GLP-1 medications need dose escalation?

Because gastrointestinal side effects depend more on how fast the dose rises than on the dose itself. Holding each step for several weeks allows tolerance to develop before the next increase. Escalating faster is the most common cause of side effects severe enough to stop treatment.

What happens if I escalate faster than the label?

You substantially raise the likelihood of nausea, vomiting and constipation severe enough to interrupt treatment, without reaching the therapeutic effect any sooner in practice. The trials that established efficacy used the labelled schedules, and their adherence rates reflect that pacing.

Can I stay on a lower dose instead of escalating to maintenance?

Many people do. If you are getting an adequate response and tolerating a given step, staying there is a legitimate option to discuss with your prescriber. The maintenance dose is the maximum studied, not a target everyone must reach.

What should I do if side effects haven't settled when the next increase is due?

Holding at the current dose for another interval before increasing is a standard adjustment, and it is generally more effective than pushing through. Raise it with your prescriber rather than modifying the schedule unilaterally — the reason for the side effects matters.